Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Antares Pharma Inc. ($ATRS) stock gained over 5% in its previous trading session. It also gained 32% in the past one month. The stock has shown consistent upward movement this year. The company reported net loss for its third quarter at $6.1 million, up from $5.7 million loss it had suffered in the comparable quarter of the previous year. However, it improved its quarterly revenue from $11.1 million to $13.5 million.
However, Antares Pharma Inc. stock is likely to benefit from its strong pipeline. The company recently reported the completion of its QuickShot® testosterone (QST) clinical program. Antares reported that it is on track for submitted the New Drug Application by December 21, 2016.

Aetna Inc. ($AET) stock slumped as the company’s attempt to acquire Humana Inc. has fallen afoul of the US antitrust authorities. The deal, estimated to be worth $37 billion, has been criticized by the Justice Department as Aetna attempts to sell Humana assets to Molina Healthcare Inc.
The Justice Department is concerned with the ongoing consolidation in health insurance sector. Earlier, it had taken action against Anthem Inc.’s attempt to acquire Cigna Corp. for $48 billion. At that time, Attorney General Loretta Lynch said that such consolidation will harm the finances and the well being of American people.


• Bluebird bio ($BLUE) announced two new appointments as it appointed Susanna High as its chief operating officer. The company also named Andrew Obenshain as senior vice president and head of Europe.
• Catalyst Biosciences ($CBIO) has been notified by NASDAQ that it is no longer in compliance with its listing requirement of a $1 minimum bid price. It has 180 days to address this issue before facing possible delisting.

• GlaxoSmithKline's ($GSK) announced that The Japanese Ministry of Health, Labour and Welfare approves the use of Relvar Ellipta (fluticasone furoate/vilanterol 100/25 mcg) for the treatment of symptoms associated with chronic obstructive pulmonary disease (COPD).
• Allergan ($AGN) and Qualicaps Co. Ltd. Reported that they have settled their patent infringement litigation with Zydus Pharmaceuticals and Cadilla Healthcare Limited. The case was related to U.S. Patent No. 6,649,180 covering ulcerative colitis med DELZICOL (mesalamine). The settlement allows Zydus and Cadilla to market their generic versions of DELZICOL in the U.S. beginning March 1, 2020 or earlier under certain circumstances.

• Boston Scientific (NYSE:BSX) inks a deal with Neovasc (NASDAQ:NVCN) to acquire certain manufacturing assets and capabilities in its advanced biological tissue business in addition to a 15% equity stake for $75M in cash. The acquired business makes elements used in transcatheter heart valves, including BSX's Lotus Valve System. It will be folded into Boston's structural heart unit when the deal closes later this month.
• Teleflex ($TFX) has agreed to acquired Vascular Solutions ($VASC), a manufacturer of tools for minimally invasive coronary and peripheral vascular procedures. The company’s shares have been priced at $56 per share. The transaction is expected to be worth nearly $1 billion and is expected to be closed in the first half of the next year.

• Pfizer ($PFE) received initial raring of Neutral from Guggenheim.
• Aimmune Therapeutics (NASDAQ: AIMT) received Buy rating from Webbush. The price target for the stock is set at $42.

Gainers (% price change) Last Trade Change Mkt Cap
Dynavax Tech. Corp.
4.70 +0.35 (8.05%) 183.19M
HealthStream, Inc.
26.03 +1.79 (7.38%) 799.15M
BioCryst Pharmaceuticals
5.51 +0.34 (6.47%) 376.24M
Antares Pharma Inc
2.03 +0.10 (5.18%) 300.80M
Exelixis, Inc.
17.37 +0.85 (5.15%) 4.86B
Losers (% price change)
Derma Sciences Inc
4.50 -0.25 (-5.26%) 125.89M
PDL BioPharma Inc
2.10 -0.11 (-4.98%) 350.81M
Codexis, Inc.
4.45 -0.20 (-4.30%) 179.57M
Oclaro, Inc.
8.02 -0.35 (-4.18%) 1.25B
GenVec Inc
3.02 -0.13 (-4.13%) 715.86M
Most Actives (dollar volume)
Eli Lilly and Co
67.71 +1.74 (2.64%) 73.47B
Johnson & Johnson
111.96 +0.58 (0.52%) 304.81B
Gilead Sciences, Inc.
72.42 -0.42 (-0.58%) 94.30B
Pfizer Inc.
31.63 +0.17 (0.54%) 187.88B
UnitedHealth Group Inc
160.73 -0.21 (-0.13%) 155.52B